Form 4 Filing for Alaunos Therapeutics, Inc.

This filing details a transaction by Holger Weis, the Chief Executive Officer of Alaunos Therapeutics, Inc. On June 12, 2026, Weis acquired 7,761 shares of common stock at a price of $2.26 per share. These shares were issued in lieu of net salary. Following this transaction, Weis now owns 12,672 shares of common stock, with ownership designated as direct.